Roxanol (Morphine Sulfate Oral Solution) Remains a Standard Hospice Medication
Yes, Roxanol—or more accurately, oral morphine sulfate solution—continues to be prescribed extensively in hospice care and remains the gold standard first-line opioid for pain and dyspnea management in end-of-life care. 1
Current Clinical Practice
The most recent NCCN guidelines (2025) explicitly recommend morphine as the standard starting drug of choice for opioid-naïve patients, with oral administration being the preferred route 1. For hospice patients specifically:
- Initial dosing: 5-15 mg of oral short-acting morphine sulfate every 2-4 hours as needed for opioid-naïve patients
- Frail or elderly patients: Consider using half-tablet doses (2.5-5 mg) for gentler titration 1
- Dyspnea management: 2.5-10 mg PO every 2 hours as needed for patients in the weeks-to-days phase of dying 2
Evidence of Widespread Use
Real-world hospice data confirms morphine's dominant role:
- 87% of hospice patients received morphine on their day of death (compared to only 21% at admission) 3
- Morphine was prescribed to 86.8% of patients on the day they died in home hospice settings 4
- Among the three most prescribed medications in palliative care centers, morphine ranks first, followed by midazolam and haloperidol 3
Why Morphine Remains Preferred
The 2025 NCCN guidelines emphasize several advantages 1:
- Wide range of formulations: Available in oral, parenteral, and rectal delivery routes
- Easy titration: Short half-life allows for more predictable dose adjustments compared to long-acting opioids like methadone
- Superior efficacy: Demonstrated significantly higher response rates and earlier onset compared to "weak opioids" (codeine, tramadol) for moderate cancer pain
- Better quality of life: Overall well-being and symptom burden rated significantly better with low-dose morphine versus weak opioids
Route of Administration Evolution
A critical shift occurs as patients approach death:
- At admission: 89% receive oral medications 3
- At day of death: 94% receive subcutaneous administration 3
This transition reflects practical realities—patients lose ability to swallow as death approaches. The parenteral equivalent dose is one-third of the oral dose (e.g., 2-5 mg IV/subcutaneous for opioid-naïve patients) 1.
Important Caveats
Renal function monitoring: Morphine should be used with caution in patients with fluctuating renal function due to accumulation of morphine-6-glucuronide, an active metabolite that can cause neurologic toxicity 1. Consider alternative opioids (hydromorphone, fentanyl) in significant renal impairment.
Administration challenges: Despite frequent prescribing, actual administration rates by informal caregivers at home are surprisingly low—only 30.68% of prescribed morphine was administered on the day of death in one study 4. This suggests caregivers need more guidance, particularly with flexible "as needed" regimens versus structured schedules.
Individual variability: Expect enormous variation in required doses. Studies show 25-fold differences in plasma morphine concentrations after identical doses 5, and daily morphine equivalent doses ranging from 10 to 735 mg in home hospice patients 6.
Practical Prescribing Algorithm
For hospice patients with pain or dyspnea:
- Start with oral morphine sulfate solution 5-15 mg every 4 hours scheduled, plus same dose every 2 hours as needed for breakthrough
- Titrate upward by 25-50% every 24-48 hours based on breakthrough dose requirements
- Switch to subcutaneous route when swallowing becomes difficult (reduce dose to one-third)
- Consider alternatives (hydromorphone, fentanyl) only if morphine causes intolerable side effects or significant renal dysfunction develops
The brand name "Roxanol" may be less commonly used today, but the medication itself—concentrated oral morphine sulfate solution—remains the cornerstone of hospice symptom management in 2025.